Benzinga

Benzinga Korea 한국

Benzinga

Benzinga Korea 한국

Benzinga

Benzinga Korea 한국
수요일, 8월 19

BeOne Medicines Ltd

ONCNASDAQ
Trade with Public
Trade with Public
$373.01
3.861.05%
마지막 업데이트: Aug 19, 9:36 AM
개요뉴스실적 전망이벤트목표가재무심리지분 현황비교옵션주식 보고서

BeOne Medicines Analyst Price Targets

Wall Street analyst price targets and consensus rating for BeOne Medicines (ONC).

Price Target Range — 7 Quarters

Analyst Consensus — 16 Analysts

2S.Buy
14Buy
Consensus RatingBuy# Analysts16Avg. Consensus PT$384Upside to Avg. PT+3.0%

Rating Trend — Last 9 Months

Recent Analyst Actions

View all ratings →
DateFirmAnalystActionRating ChangePrice Target
Aug 6, 2026TD CowenYaron WerberPT RaiseBuy$424→$454
Aug 6, 2026RBC CapitalLeonid TimashevPT CutOutperform$451→$450
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
TD Cowen Maintains Buy on BeOne Medicines, Raises Price Target to $454

TD Cowen analyst Yaron Werber maintains BeOne Medicines (NASDAQ:ONC) with a Buy and raises the price target from $424 to $454.
Benzinga Newsdesk

PRO
RBC Capital Maintains Outperform on BeOne Medicines, Lowers Price Target to $450

RBC Capital analyst Leonid Timashev maintains BeOne Medicines (NASDAQ:ONC) with a Outperform and lowers the price target from $451 to $450.
Benzinga Newsdesk

PRO
Truist Securities Maintains Buy on BeOne Medicines, Raises Price Target to $418

Truist Securities analyst Gregory Renza maintains BeOne Medicines (NASDAQ:ONC) with a Buy and raises the price target from $416 to $418.
Benzinga Newsdesk

PRO
Guggenheim Maintains Buy on BeOne Medicines, Raises Price Target to $430

Guggenheim analyst Michael Schmitz maintains BeOne Medicines (NASDAQ:ONC) with a Buy and raises the price target from $420 to $430.
Benzinga Newsdesk

PRO
Citizens Maintains Market Outperform on BeOne Medicines, Raises Price Target to $405

Citizens analyst Reni J. Benjamin maintains BeOne Medicines (NASDAQ:ONC) with a Market Outperform and raises the price target from $396 to $405.
Benzinga Newsdesk

PRO
JP Morgan Maintains Overweight on BeOne Medicines, Raises Price Target to $425

JP Morgan analyst Jessica Fye maintains BeOne Medicines (NASDAQ:ONC) with a Overweight and raises the price target from $415 to $425.
Benzinga Newsdesk

데이터 및 API: Benzinga API · 주식 뉴스 API · 애널리스트 등급 API · 회사 로고 API

시장 데이터 제공 Benzinga API

Benzinga

Benzinga Korea 한국

뉴스

파트너 / 기고자

벤징가 글로벌

© 2026 Benzinga | All Rights Reserved